OR WAIT null SECS
CatSci has opened its new Dagenham, UK-based laboratory, which is dedicated to analytical excellence.
CatSci’s new analytical sciences laboratory in Dagenham, UK, is now open and will focus on combining analytical and synthetic chemistry expertise with the latest high-end equipment to solve current and future complex problems in the pharmaceutical industry. The new facility, launched in June 2021, will further cement the company’s position in the United Kingdom, making it a center for excellence in pharmaceutical research and development, the company stated in a June 8, 2021 press release.
The new facility is fully equipped with state-of-the-art analytical equipment, through a collaboration with Shimadzu, and provides high-quality analytical data and critical interpretation. The facility is a key early milestone in CatSci’s £3 million (US$4.15 million) investment plan and will better equip the company to meet the demand for solving multi-disciplinary analytical problems, which are growing because of the progress of new modalities and asset classes, such as oligonucleotides and cannabinoids. At the same time, new or modified regulatory requirements, such as nitrosamine determinations and trace impurity analysis, require the development of highly specific and sensitive methods.
“The opening of our analytical laboratory at LondonEast in Dagenham, UK, is an exciting step on our journey towards becoming a fully integrated CMC [chemistry, manufacturing, and controls] company that accelerates medicine development to deliver best-in-class therapeutics to those in need. Solving complex challenges that our customers face is at the core of what we do, and this new facility, filled with Shimadzu’s cutting-edge equipment, sets a new exemplary standard for measurement science in the industry,” said Ross Burn, CEO, CatSci in the company press release.
“The opening of this new facility deepens the level of support we can offer,” added Nigel Richardson, director of Analytical Technology & New Modalities, CatSci, in the press release. “We will also be upgrading the site with capacity for GMP [good manufacturing practice] analytical development and testing, which will further increase our ability to provide innovative, tailored solutions from early development pre-clinical data packages to late development Phase III impurity fate studies.”